Non-HLA antibodies in solid organ transplantation: Recent concepts and clinical relevance

Current Opinion in Organ Transplantation

Volumn 18, Issue 4, 2013, Pages 430-435

  Dragun, Duska ^a   Catar, Rusan ^a   Philippe, Aurélie ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

anti collagen V antibodies; anti K 1 tubulin antibodies; anti perlecan antibodies; AT1R antibodies; ETAR antibodies

Indexed keywords

ALPHA TUBULIN; ANGIOTENSIN 1 RECEPTOR; CATHEPSIN L; COLLAGEN TYPE 5; ENDOTHELIN; ENDOTHELIN A RECEPTOR; GAMMA INTERFERON; HLA ANTIBODY; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; PERLECAN; PROCOLLAGEN C PROTEINASE;

ACUTE GRAFT REJECTION; ALLOGRAFT; ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; APOPTOSIS; AUTOIMMUNITY; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL STUDY; CONCEPTUAL FRAMEWORK; ENDOTHELIUM CELL; FOCAL GLOMERULOSCLEROSIS; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEREDITY; HUMAN; HUMORAL IMMUNITY; IMMUNOBLOTTING; ISCHEMIA; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MICROENVIRONMENT; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PREECLAMPSIA; PULMONARY HYPERTENSION; REVIEW;

AUTOANTIBODIES; COLLAGEN TYPE V; HEPARAN SULFATE PROTEOGLYCANS; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ORGAN TRANSPLANTATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; TUBULIN;

EID: 84880919838     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283636e55     Document Type: Review

References (33)

1. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569
2. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90:1473-1477
3. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70:530-536
4. Giral MFY, Dufay A, Van Huyen JPD, et al. Pretransplant sensitization against angiotensin II Type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013; in press
5. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013; 368:971-973
6. Harrison-Bernard LM, Navar LG, Ho MM, et al. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997; 273:F170-F177
7. Lachmann NDD, Todorova K, Heidecke H, et al. Anti-angiotensin II type 1 receptor antibodies accelerate late renal allograft failure in the absence or presence of HLA antibodies; 24th International Congress of the Transplantation Society; 2012
8. Yamani MH, Cook DJ, Tuzcu EM, et al. Systemic up-regulation of angiotensin II type 1 receptor in cardiac donors with spontaneous intracerebral hemorrhage. Am J Transplant 2004; 4:1097-1102
9. Yamani MH, Cook DJ, Rodriguez ER, et al. Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection. J Heart Lung Transplant 2006; 25:1283-1289
10. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444-1449
11. Sutherland AJ, Nataatmadja MI, Walker PJ, et al. Vascular remodeling in the internal mammary artery graft and association with in situ endothelin-1 and receptor expression. Circulation 2006; 113:1180-1188
12. Hiemann NE, Meyer R, Wellnhofer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94:919-924
13. Sarma NJ, Tiriveedhi V, Angaswamy N, Mohanakumar T. Role of antibodies to self-antigens in chronic allograft rejection: Potential mechanism and therapeutic implications. Hum Immunol 2012; 73:1275-1281
14. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: Role in chronic lung allograft rejection. J Immunol 2008; 180:4487-4494
15. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117:3498-3506
16. Hachem RR, Tiriveedhi V, Patterson GA, et al. Antibodies to K-alpha 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant 2012; 12:2164-2171
17. Nath DS, Tiriveedhi V, Basha HI, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011; 91:1036-1043
18. Davis GE. Matricryptic sites control tissue injury responses in the cardiovascular system: Relationships to pattern recognition receptor regulated events. J Mol Cell Cardiol 2010; 48:454-460
19. Cailhier JF, Sirois I, Laplante P, et al. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J Biol Chem 2008; 283:27220-27229
20. Soulez M, Sirois I, Brassard N, et al. Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate ERK1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells 2010; 28:810-820
21. Soulez M, Pilon EA, Dieude M, et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ Res 2012; 110:94-104
22. Cardinal H, Dieude M, Brassard N, et al. Anti-perlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant 2013; 13:861-874
23. Porcheray F, DeVito J, Helou Y, et al. Expansion of polyreactive B cells crossreactive to HLA and self in the blood of a patient with kidney graft rejection. Am J Transplant 2012; 12:2088-2097
24. Clatworthy MR, Espeli M, Torpey N, Smith KG. The generation and maintenance of serum alloantibody. Curr Opin Immunol 2010; 22:669-681
25. Thaunat O, Nicoletti A. Lymphoid neogenesis in chronic rejection. Curr Opin Organ Transplant 2008; 13:16-19
26. Thaunat O, Graff-Dubois S, Fabien N, et al. A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int 2012; 81:207-219
27. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: When allo is not enough. Transplantation 2010; 90:113-120
28. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibodyinduced autoimmunity: Role in chronic rejection. Curr Opin Organ Transplant 2010; 15:16-20
29. Dragun D, Catar R, Kusch A, et al. Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012; 73:1282-1286
30. Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14:855-862
31. Kelsch R, Everding AS, Kuwertz-Broking E, et al. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation 2011; 92:e57-e59
32. Lukitsch I, Kehr J, Chaykovska L, et al. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012; 94:8-13
33. Kranz B, Kelsch R, Kuwertz-Broking E, et al. Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 2011; 26:1149-1156 Treatment (SysKID)